RxDoctor Payments DataLook up a doctor →

Jessica Myers, NP

Psychiatric/Mental Health · Sullivan, INNPI 1902278476

Payments from drug & device makers

$8,034in general payments, 2019–2025

Across 427 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Harmony Biosciences LLC$856
  • Boehringer Ingelheim$814
  • AstraZeneca$765
  • Jazz Pharmaceuticals Inc.$641
  • Electromed, Inc.$529
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,63095%
  • Education$4045%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,034 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$11,707
Medicare patients
69
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor11$145,533
Trelegy ElliptaFluticasone/Umeclidin/Vilanter157$120,175
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$42,902
Dupixent PenDupilumab11$40,999
CaplytaLumateperone Tosylate11$17,911
Breo ElliptaFluticasone/Vilanterol32$14,875
Spiriva RespimatTiotropium Bromide16$10,383
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,000
Albuterol Sulfate HfaAlbuterol Sulfate217$5,172
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$1,761
Armodafinil22$1,697
Ventolin HfaAlbuterol Sulfate21$1,156
Bupropion XlBupropion Hcl20$1,078
Modafinil13$914
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$279$145,53311 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,268$141,050202 claims
AstraZenecaBreztri Aerosphere$765$42,90251 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$155$17,91111 claims
Boehringer IngelheimSpiriva Respimat$814$10,38316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Sullivan

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →